Cancers, Vol. 11, Pages 984: Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?

Cancers, Vol. 11, Pages 984: Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME? Cancers doi: 10.3390/cancers11070984 Authors: Ghaneya Al-Khadairi Julie Decock PRAME or PReferentially expressed Antigen in Melanoma is a testis-selective cancer testis antigen (CTA) with restricted expression in somatic tissues and re-expression in various cancers. It is one of the most widely studied CTAs and has been associated with the outcome and risk of metastasis. Although little is known about its pathophysiological function, PRAME has gained interest as a candidate target for immunotherapy. This review provides an update on our knowledge on PRAME expression and function in healthy and malignant cells and the current immunotherapeutic strategies targeting PRAME with their specific challenges and opportunities. We also highlight some of the features that position PRAME as a unique cancer testis antigen to target.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research

Related Links:

Publication date: Available online 17 August 2019Source: Seminars in Cancer BiologyAuthor(s): Paola Queirolo, Andrea Boutros, Enrica Tanda, Francesco Spagnolo, Pietro QuaglinoAbstractMelanoma has always been described as an immunogenic tumor. Despite that, until 2011 the standard of care in metastatic melanoma was chemotherapy, with low response rates and no clear impact on overall survival. Melanoma was the first cancer type to drive the use of immune-checkpoint inhibitors into clinical practice, which revolutionized the therapeutic paradigm not only in melanoma, but also in an increasing number of tumors. In this review,...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
We describe a case series of nine patients with metastatic melanoma and injectable lesions who developed progressive disease under a PD-1 inhibitor monotherapy. At the time of progressive disease, patients received intratumoral IL-2 treatment in addition to PD-1 inhibitor therapy. Three patients showed complete, three patients partial response and three patients progressive disease upon this combination therapy. IHC stainings were performed from metastases available at baseline (start of PD-1 inhibitor) and under combination therapy with IL-2. IHC results revealed a significant increase of CD4+ and CD8+ T cells and a highe...
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
Patients with mesothelioma are now eligible for a multicancer clinical trial studying the effectiveness of personalized immunotherapy at the University of California, San Diego Medical Center. The phase I clinical trial involves a combination of Keytruda (pembrolizumab), a proven immunotherapy drug, and an individualized vaccine based upon the genetic mutations found in each patient’s cancer. “This is the future of cancer treatment,” Dr. Ezra Cohen, principal investigator and director of the San Diego Center for Precision Immunotherapy, told The Mesothelioma Center at Asbestos.com. “Now, we still ha...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Abstract CD40 is a cell-surface member of the TNF (tumor necrosis factor) receptor superfamily. Upon activation, CD40 can license dendritic cells to promote antitumor T cell activation and re-educate macrophages to destroy tumor stroma. Numerous agonist CD40 antibodies of varying formulations have been evaluated in the clinic and found to be tolerable and feasible. Administration is associated with mild to moderate (but transient) cytokine release syndrome, readily managed in the outpatient setting. Antitumor activity with or without anti-CTLA4 monoclonal antibody (mAb) therapy has been observed in patients with m...
Source: Annual Review of Medicine - Category: General Medicine Authors: Tags: Annu Rev Med Source Type: research
ConclusionThese results demonstrated the potential usage of a piTRL with laser irradiation for immuno-photothermal therapy against various types of cancer and their metastases.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
When TJ Sharpe was diagnosed with Stage 4 melanoma in August 2012, his future looked bleak. He was 37 years old with two young children, the median lifespan for patients with his diagnosis was 18 months and treatment options were limited.Thanks to some knowledge of the pharmaceutical industry he soon realised his best chance of survival was to find a clinical trial. It was a daunting prospect, but his resolve was solid and, after undergoing six surgical operations and four immunotherapy treatments across two different clinical trials, he lived to tell the tale.“I was lucky,” says Sharpe, “I was aware of c...
Source: EyeForPharma - Category: Pharmaceuticals Authors: Source Type: news
ConclusionsOverall, this study demonstrates that modulation of the immunosuppressive TIME is required to unlock the benefits of ICIs and radiotherapy to induce immunologic rejection of treatment-refractory established solid tumors.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
Abstract Melanoma is the most aggressive form of skin cancer, with a high mortality rate and with 96,480 new cases expected in 2019 in the USS. BRAFV600E, the most common driver mutation, is found in around 50% of melanomas, contributing to tumor growth, angiogenesis, and metastatic progression. Dacarbazine (DTIC), an alkylate agent, was the first chemotherapeutic agent approved by the US Food and Drug Administration (FDA) used as a standard treatment. Since then, immunotherapies have been approved for metastatic melanoma (MM) including ipilimumab and pembrolizumab checkpoint inhibitors that help decrease the risk...
Source: Applied Microbiology and Biotechnology - Category: Microbiology Authors: Tags: Appl Microbiol Biotechnol Source Type: research
Publication date: Available online 9 August 2019Source: Seminars in Cancer BiologyAuthor(s): Monica Marzagalli, Nancy D. Ebelt, Edwin R. ManuelAbstractCutaneous melanoma is the most common skin cancer with an incidence that has been rapidly increasing in the past decades. Melanomas are among the most immunogenic tumors and, as such, have the greatest potential to respond favorably to immunotherapy. However, like many cancers, melanomas acquire various suppressive mechanisms, which generally act in concert, to escape innate and adaptive immune detection and destruction. Intense research into the cellular and molecular event...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
ConclusionThe new HSV-1 based platform described provides a potent and versatile approach to developing new oncolytic immunotherapies for clinical use. Each of the modifications employed was demonstrated to aid in optimizing the potential of the virus to both directly kill tumors and to lead to systemic therapeutic benefit. For clinical use, these viruses are expected to be most effective in combination with other anti-cancer agents, in particular PD1/L1-targeted immune checkpoint blockade. The first virus from this program (expressing GALV-GP-R− and hGM-CSF) has entered clinical development alone and in combination ...
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Immunotherapy | Melanoma | Skin Cancer